Results 201 to 210 of about 1,972,419 (251)
Some of the next articles are maybe not open access.
2007
Platelet-activating factor (PAF) is a potent mediator that occurs at very low concentrations in cells and tissues. Accurate quantitation of PAF has always been difficult because of the physicochemical properties of PAF and its structural similarity to several much more abundant phospholipids.
John S, Owen +2 more
openaire +2 more sources
Platelet-activating factor (PAF) is a potent mediator that occurs at very low concentrations in cells and tissues. Accurate quantitation of PAF has always been difficult because of the physicochemical properties of PAF and its structural similarity to several much more abundant phospholipids.
John S, Owen +2 more
openaire +2 more sources
Hospital Practice, 1983
Our ability to chemically characterize and synthesize this autacoid of allergy and inflammation has given us a unique opportunity to study these important molecules in a highly disciplined fashion. It has also opened the door to a vista of research approaches to define PAF's normal physiologic role as well as its actions as an immunopathologic mediator.
openaire +2 more sources
Our ability to chemically characterize and synthesize this autacoid of allergy and inflammation has given us a unique opportunity to study these important molecules in a highly disciplined fashion. It has also opened the door to a vista of research approaches to define PAF's normal physiologic role as well as its actions as an immunopathologic mediator.
openaire +2 more sources
Stress and Platelet Activation
Acta Haematologica, 2009Severe stress, with increased secretion of adrenaline, is likely to cause platelet activation. The aim of the present study was to investigate if moderate stress, which usually is not accompanied by adrenaline secretion, could induce activation of platelets, as measured by changes in the plasma concentrations of platelet factor 4 (PF-4).
L, Andrén +3 more
openaire +2 more sources
Headache: The Journal of Head and Face Pain, 1982
SYNOPSIS Migraine is a disease associated with increased platelet activity. The aim of this paper was to study "in vivo" platelet activation by assessing platelet serotonin (5HT) content and beta‐thromboglobulin (B‐TG) and platelet factor four (PF4) plasma levels, in headache‐free‐periods and during migraine attacks.
G, D'Andrea +3 more
openaire +2 more sources
SYNOPSIS Migraine is a disease associated with increased platelet activity. The aim of this paper was to study "in vivo" platelet activation by assessing platelet serotonin (5HT) content and beta‐thromboglobulin (B‐TG) and platelet factor four (PF4) plasma levels, in headache‐free‐periods and during migraine attacks.
G, D'Andrea +3 more
openaire +2 more sources
Platelet activation by heparin
Blood, 2011In this issue of Blood , Gao et al provide important insights into the proactivating effects of negatively charged anticoagulants on platelets.[1][1] They show outside-in signaling via the glycoprotein (GP) IIb-IIIa complex (integrin αIIbβ3) induced by heparin, low molecular weight heparin ...
openaire +2 more sources
Artificial Organs, 2000
Abstract: Activated clotting time (ACT) is the most commonly used laboratory test to control the heparin effect during extracorporeal techniques. The study was undertaken in order to test in vitro the influence of heparin, platelet count, hematocrit, platelet fragmentation, and platelet activation on ACT.
L, Girardi, K, Sudi, W, Muntean
openaire +2 more sources
Abstract: Activated clotting time (ACT) is the most commonly used laboratory test to control the heparin effect during extracorporeal techniques. The study was undertaken in order to test in vitro the influence of heparin, platelet count, hematocrit, platelet fragmentation, and platelet activation on ACT.
L, Girardi, K, Sudi, W, Muntean
openaire +2 more sources
The role of platelet-activating factor in platelet aggregation
Nature, 1979PLATELET aggregation is mediated by at least three distinct mechanisms1,2. The first involves the release of ADP and is inhibited by its conversion to ATP by the combination of creatine phosphate and creatine phosphokinase (CP/CPK). The second is mediated by metabolites of arachidonic acid, particularly thromboxane A2 (TXA2), and is blocked by aspirin ...
M, Chignard +4 more
openaire +2 more sources
Desensitization of human platelets by platelet activating factor
Biochemical and Biophysical Research Communications, 1985Human platelets are less responsive to PAF at 37 degrees than at 25 degrees. They can be desensitized to the effects of PAF by pre-exposure to small concentrations. In both cases desensitization appears to be accompanied by a decreased affinity of the high affinity site for PAF rather than loss of binding sites.
C M, Chesney, D D, Pifer, K M, Huch
openaire +2 more sources
Platelet antiaggregate activity
American Heart Journal, 1991Calcium ions act as a second messenger to platelet agonists, with increases in intracellular calcium bringing about changes in shape, aggregation, and release reactions. Changes in platelet function have been reported previously in migraine sufferers and there is evidence that hyperaggregability occurs during a migraine attack. It was decided to assess
openaire +2 more sources
Platelet Microparticles: A Carrier of Platelet-Activating Factor?
Biochemical and Biophysical Research Communications, 1996Platelet-activating factor (PAF) has been considered to be released in a soluble form from activated platelets. Also a considerable number of microparticles were released from stimulated platelets. To evaluate the possibility that microparticles contain PAF, the amount of PAF in whole activated platelets, microparticles and the suspending medium was ...
S, Iwamoto +4 more
openaire +2 more sources

